China's 'Beinao-1' Brain-Computer Interface Restores Movement in Seven Patients

China has taken a major step forward in brain-computer interface (BCI) technology after successfully implanting its semi-invasive 'Beinao-1' system in seven patients. All recipients recovered well, regaining movement and speech functions. The breakthrough comes as the country accelerates its push to become a global leader in the sector.

At the 2026 Zhongguancun Forum in Beijing, experts showcased two domestically developed BCI systems, 'Beinao-1' and 'Beinao-2', highlighting rapid progress in medical applications.

BCI technology creates a direct link between the brain and external devices, allowing patients to control assistive tools through thought alone. In recent years, medical centres across Chinese cities have established specialised BCI clinics and research wards to advance clinical trials.

China made history in March 2026 when its National Medical Products Administration approved the world's first invasive BCI medical device for commercial use. This milestone followed extensive research and positioned China alongside the United States—the only two countries with officially approved or clinically trialled BCI technologies for medical use. While the US led in invasive trials, China achieved the first market approval. At the Zhongguancun Forum, neurosurgery expert Zhao Jizong, an academician with the Chinese Academy of Sciences, presented the latest advancements in BCI research. The event also featured an exhibition of cutting-edge BCI products, including 'Beinao-1' and 'Beinao-2'. The latter system is set to enter clinical verification later this year. The government has designated BCI as a future industry, introducing policies to boost research and industrial growth. Beijing's Haidian District, a key innovation hub, aims to attract around 100 BCI-focused small and medium-sized enterprises by 2030.

The successful implantation of 'Beinao-1' marks a significant achievement for China's BCI sector. With regulatory approvals, ongoing clinical trials, and ambitious industry targets, the country is expanding its role in medical innovation. Further developments, including the upcoming verification of 'Beinao-2', are expected to strengthen its position in the field.